ClinicalTrials.gg
Active, not recruitingNCT06523153Updated Nov 19, 2024

A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants

A Phase 1 interventional study of VYD2311 and Placebo in COVID-19, sponsored by Invivyd, Inc.. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by Invivyd, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in COVID-19 with a site in Australia — 6 open to participants now, 15 under way, 8 of them phase 3. COVID-19 · Australia.

Planned enrollment
58th of 79
40 · median 185
Started
2024
with 5 others
Phase 1
28 of 89
1 open now
Primary completion
2025-05
later than 3 of 14 live
Registered
87th of 89
by date

Among the 89 studies in COVID-19 with a site in Australia, this one is the 58th largest by planned enrollment of the 79 interventional ones that give a count, is one of 6 that started in 2024, is one of 28 in phase 1, reaches primary completion later than 3 of the 14 other live ones, and was the 87th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 89 studies in COVID-19 with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in COVID-19 with a site in Australia, or all of them as a file.
02

Study summary

A study to investigate the safety, tolerability, and pharmacokinetics of a SARS-CoV-2-directed monoclonal antibody in healthy participants

Read the detailed description

This is a Phase I, first-in-human, randomized, double blind, placebo controlled, single escalating dose study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of VYD2311, a monoclonal antibody targeting SARS-CoV-2, in healthy volunteers.

The primary objective is to evaluate the safety and tolerability of multiple dose levels of VYD2311 after a single IV, IM, or SC administration in healthy participants. The secondary objectives are to evaluate the PK of VYD2311 after IV or IM administration and the immunogenicity of VYD2311 after IV, IM, or SC administration in healthy participants.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a male or female participant aged 18 to 65 years, inclusive.
  • Has a 18.0 to 32.0 kg/m2, inclusive.
  • Is in good health, with no abnormalities as determined by the Investigator based on medical history, physical exam, vital signs, , and laboratory values per study unit standard operating procedures.
  • Tests negative for current SARS-CoV-2 infection by rapid antigen test on screening and Day -1.
  • For participants assigned female sex at birth:

    • Is not of (defined in protocol), OR
    • Is of childbearing potential (defined in protocol) and practicing highly effective (defined in protocol) for at least 28 days before dosing (Day 1) through 6 months after dosing and has negative results on pregnancy tests at Screening and on Day -1.
  • Is able and willing to provide written .
  • Is able to understand the study procedures and willing to adhere to all protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Has a known or suspected allergy, intolerance, or to any component of the study drug, including and closely related compounds (eg, other mAbs).
  • Intends to receive a COVID-19 vaccine/booster within 3 months of Day 1.
  • Is pregnant, breastfeeding, or seeking pregnancy while on study.
  • Has any chronic or significant medical condition that, in the assessment of the Investigator, might compromise participant safety or interfere with evaluation of the study drug or interpretation of participant safety/study results, including but not limited to significant neurologic, renal, hepatic, hematologic, immune, cardiac, pulmonary, metabolic, endocrine, psychiatric, vascular, or gastrointestinal disorders.
  • Has a history of a (or active malignancy), except for participants with basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the cervix who have been treated and cured.
  • Has had any symptoms of acute respiratory illness (eg, cough, shortness of breath, sore throat, fatigue, loss of smell, fever), or other febrile illness within 2 weeks prior to dosing.
  • Has evidence of active infection with , , or , as indicated by any of the following: positive antibody, antigen, or nucleic acid amplification test result for HIV; positive HBV surface antigen; positive HCV antibody with positive HCV RNA (positive antibody test with negative RNA test is not exclusionary).
  • Has current alcoholism or recreational drug use, including a positive test result for marijuana, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines, or alcohol.
  • Is a current or former regular cigarette smoker (more than 5 cigarettes per day within the last year). Individuals who currently or previously smoked 5 or fewer cigarettes per day are allowed if they agree to abstain from smoking during confinement at the CRU.
  • Has donated more than 500 mL of blood within 60 days before the scheduled dose of study drug.
  • Had major surgery within 30 days prior to study drug dosing or has planned surgeries within 12 months after planned study drug dosing.
  • Received any drug or biologic within 30 days or 5 half-lives (whichever is longer) prior to Screening or planned administration of any investigational drug or biologic during the study period.
  • Received immunoglobulin or blood products within 6 months prior to Screening
  • Previously received a mAb within 6 months or 5 half-lives (whichever is longer) prior to Screening or previously received pemivibart (VYD222) at any time.
  • Has taken prescription or OTC medications or supplements within 5 half-lives of the specific substance (or, if half-life is not known, within 48 hours) before the scheduled administration of study drug, with the following exceptions:

    • Influenza or COVID-19 vaccination more than 14 days prior to dosing, or any other vaccine more than 4 weeks prior to dosing
    • Hormonal
    • Standard of care use of acetaminophen/paracetamol
    • Vitamins and other nutritional supplements that are not newly introduced (ie, have been taken for at least 30 days prior to enrollment)
    • Other OTC medications that, in the judgement of the Investigator or medically qualified designee, will not impact the safety of the participant or data integrity of the study.
  • Screening or predose systolic blood pressure that repeatedly measures below approximately 100 mm Hg. If systolic blood pressure measures below 100 mm Hg, the measurement may be repeated twice. If the average of all three measurements is greater than or equal to 100 mm Hg, the participant may be considered eligible as determined by the Investigator or medically qualified designee.
  • In the opinion of the Investigator, is unable to comply with the study protocol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    VYD2311

    Injection in healthy volunteer

    Biological: VYD2311

  • Placebo comparator
    Placebo

    Injection in healthy volunteer

    Other: Placebo

Interventions

  • BiologicalVYD2311

    Monoclonal antibody

  • OtherPlacebo

    Matching Placebo

    Also known as: 0.9% sodium chloride

06

What researchers measure

Primary outcomes

  1. Incidence of TEAEs (including AEs and SAEs)

    Time frame: Through Month-6 visit

Secondary outcomes

  1. PK parameter of VYD2311, AUC0-inf (area under the concentration-time curve from time 0 extrapolated to infinity)

    Time frame: Through Month-6 visit

  2. PK parameter of VYD2311, AUClast (area under the concentration-time curve from time 0 to the last quantifiable concentration)

    Time frame: Through Month-6 visit

  3. PK parameter of VYD2311, AUC0-t (area under the concentration-time curve from time 0 to t)

    Time frame: Through Month-6 visit

  4. PK parameter of VYD2311, Cmax (maximum serum concentration)

    Time frame: Through Month-6 visit

  5. PK parameter of VYD2311, Tmax (time to reach maximum serum concentration)

    Time frame: Through Month-6 visit

  6. PK parameter of VYD2311, CL (clearance)

    Time frame: Through Month-6 visit

  7. PK parameter of VYD2311, t1/2 (half-life)

    Time frame: Through Month-6 visit

  8. PK parameter of VYD2311, Vss (apparent volume of distribution at steady state)

    Time frame: Through Month-6 visit

  9. PK parameter of VYD2311, Vz (apparent volume of distribution during terminal phase)

    Time frame: Through Month-6 visit

  10. Incidence of ADAs against VYD2311

    Time frame: Through Month-6 visit

07

Study locations

1 site
  • Invivyd Investigative Site
    Joondalup, WA 6027, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for May 2025, 9 months after the start.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 9 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2024
First posted
Jul 26, 2024
StartActual
Aug 28, 2024
Primary completionEst.
May 2025
CompletionEst.
May 2025
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06523153
Lead sponsor
Invivyd, Inc.
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Jul 26, 2024
Start date
Aug 28, 2024
Primary completion
May 2025 (estimated)
Completion
May 2025 (estimated)
Last update
Nov 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibramvibart

Start the discussion